Imperial College London

DrLeilaJanani

Faculty of MedicineSchool of Public Health

Research Fellow (Clinical Trials Statistician)
 
 
 
//

Contact

 

l.janani

 
 
//

Location

 

Stadium HouseWhite City Campus

//

Summary

 

Summary


Leila Janani is a research fellow and clinical trial statistician at Imperial Clinical Trials Unit (ICTU). Within ICTU she is a member of the Trials Methodology team (StatsCI) and Clinical Trial Statistics group.

She completed a BSc in Statistics from Tabriz University, Iran followed by a MSc and Ph.D. in Biostatistics from Tehran University of Medical Sciences which is the highest-ranked medical university in Iran. She also attended an MBA certificate program which was held by the Sharif University of Technology. She has over 10 years of experience in teaching, designing, developing protocols, conducting, monitoring, analysing, and reporting clinical trial studies.

Leila started working as an Assistant Professor of Biostatistics at Iran University of Medical Sciences immediately after she obtained Ph.D. degree in 2015 and after 4 years, she could promote to Associate level. Additionally, she has worked as a Head of Biostatistics Unit, Clinical Trial Center (CTC), Tehran University of Medical Sciences. CTC initiated the first private knowledge-based clinical research organization (CRO) in Iran that works closely with Iran FDA to enhance the standards of conducting industry-initiated clinical trials by providing functional services to the pharmaceutical and medical device industries.

She joined the Imperial Clinical Trials Unit (ICTU) as a research fellow in January, 2021. She is currently working on the TREAT trial – Treating severe paediatric asthma and statistical research and trial design in critical care. Her research interest are in statistical methods to improve the design, analysis, and reporting of randomised clinical trials.

Publications

Journals

Liu X, Munro APS, Feng S, et al., 2022, Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial, Journal of Infection, Vol:84, ISSN:0163-4453, Pages:795-813

Munro APS, Feng S, Janani L, et al., 2022, Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial., Lancet Infect Dis

Jones T, Janani L, Gordon A, et al., 2022, A novel role for cytochrome P450 epoxygenase metabolites in septic shock, Critical Care Explorations, Vol:4, ISSN:2639-8028

Munro APS, Janani L, Cornelius V, et al., 2021, Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial, The Lancet, Vol:398, ISSN:0140-6736

Tanha K, Mottaghi A, Nojomi M, et al., 2021, Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses, Journal of Ovarian Research, Vol:14

More Publications